A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)

Authors
Category Primary study
Registry of TrialsClinical Trials Peruvian Registry
Year 2024
This article has no abstract
Epistemonikos ID: b68f3b28c61e3c46f321811276c8159b2e8680ea
First added on: Apr 11, 2025